Skip to main content

Anixa Biosciences Stock Forecast, Price & News

+0.26 (+7.51 %)
(As of 05/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume217,300 shs
Average Volume537,609 shs
Market Capitalization$116.92 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ANIX News and Ratings via Email

Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Anixa Biosciences logo

About Anixa Biosciences

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with OntoChem GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.


See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ANIX
Phone408 708 9808
Year FoundedN/A

Sales & Book Value

Annual Sales$250,000.00
Book Value$0.35 per share


Net Income$-10,020,000.00




Market Cap$116.92 million
Next Earnings Date6/8/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.59 out of 5 stars

Medical Sector

425th out of 2,042 stocks

Pharmaceutical Preparations Industry

193rd out of 769 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Anixa Biosciences (NASDAQ:ANIX) Frequently Asked Questions

Is Anixa Biosciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anixa Biosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Anixa Biosciences stock.
View analyst ratings for Anixa Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Anixa Biosciences?

Wall Street analysts have given Anixa Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Anixa Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Anixa Biosciences?

Anixa Biosciences saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 529,100 shares, a drop of 18.7% from the March 31st total of 650,500 shares. Based on an average daily volume of 632,800 shares, the short-interest ratio is presently 0.8 days.
View Anixa Biosciences' Short Interest

When is Anixa Biosciences' next earnings date?

Anixa Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, June 8th 2021.
View our earnings forecast for Anixa Biosciences

How were Anixa Biosciences' earnings last quarter?

Anixa Biosciences, Inc. (NASDAQ:ANIX) issued its quarterly earnings data on Thursday, March, 11th. The company reported ($0.09) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.11) by $0.02. The business had revenue of $0.51 million for the quarter.
View Anixa Biosciences' earnings history

How has Anixa Biosciences' stock price been impacted by COVID-19 (Coronavirus)?

Anixa Biosciences' stock was trading at $2.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ANIX stock has increased by 79.7% and is now trading at $3.72.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ANIX?

2 brokerages have issued 12 month price targets for Anixa Biosciences' shares. Their forecasts range from $11.00 to $11.00. On average, they expect Anixa Biosciences' stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 195.7% from the stock's current price.
View analysts' price targets for Anixa Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Anixa Biosciences' key executives?

Anixa Biosciences' management team includes the following people:
  • Dr. Amit Kumar Ph.D., Chairman, Pres & CEO (Age 57, Pay $720.87k)
  • Mr. Michael J. Catelani, COO, CFO & Corp. Sec. (Age 54, Pay $337.22k)
  • Mr. John Roop, Sr. VP of Engineering (Age 71)
  • Mr. Thomas Schlumpberger, Exec. VP of Diagnostics

Who are some of Anixa Biosciences' key competitors?

What other stocks do shareholders of Anixa Biosciences own?

What is Anixa Biosciences' stock symbol?

Anixa Biosciences trades on the NASDAQ under the ticker symbol "ANIX."

Who are Anixa Biosciences' major shareholders?

Anixa Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include UBS Group AG (1.87%), Geode Capital Management LLC (0.54%), BlackRock Inc. (0.33%), Wealth Alliance Advisory Group LLC (0.06%), Stifel Financial Corp (0.06%) and Concorde Asset Management LLC (0.04%). Company insiders that own Anixa Biosciences stock include Amit Kumar, Arnold M Baskies, Emily Gottschalk and Lewis H Titterton Jr.
View institutional ownership trends for Anixa Biosciences

Which major investors are selling Anixa Biosciences stock?

ANIX stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for Anixa Biosciences
or view top insider-selling stocks.

Which major investors are buying Anixa Biosciences stock?

ANIX stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Wealth Alliance Advisory Group LLC, Stifel Financial Corp, Concorde Asset Management LLC, Barclays PLC, BlackRock Inc., Dorsey Wright & Associates, and First Manhattan Co.. Company insiders that have bought Anixa Biosciences stock in the last two years include Amit Kumar, Arnold M Baskies, Emily Gottschalk, and Lewis H Titterton Jr.
View insider buying and selling activity for Anixa Biosciences
or or view top insider-buying stocks.

How do I buy shares of Anixa Biosciences?

Shares of ANIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anixa Biosciences' stock price today?

One share of ANIX stock can currently be purchased for approximately $3.72.

How much money does Anixa Biosciences make?

Anixa Biosciences has a market capitalization of $116.92 million and generates $250,000.00 in revenue each year. The company earns $-10,020,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis.

How many employees does Anixa Biosciences have?

Anixa Biosciences employs 3 workers across the globe.

What is Anixa Biosciences' official website?

The official website for Anixa Biosciences is

Where are Anixa Biosciences' headquarters?

Anixa Biosciences is headquartered at 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118.

How can I contact Anixa Biosciences?

Anixa Biosciences' mailing address is 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118. The company can be reached via phone at 408 708 9808 or via email at [email protected]

This page was last updated on 5/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.